Aptose Biosciences Inc (APTO)

Dec 19, 2024

Aptose gets Nasdaq extension to regain compliance - MSN

Dec 19, 2024

Dec 19, 2024

Aptose Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewswire

Dec 19, 2024

Dec 19, 2024

Aptose Biosciences Secures Critical Nasdaq Extension, Unveils $8M Offering and Cancer Drug Progress - StockTitan

Dec 19, 2024

Dec 14, 2024

Metrics That Matter About Aptose Biosciences Inc (NASDAQ: APTO) - Stocks Register

Dec 14, 2024

Dec 13, 2024

SEC Form PRE 14A filed by Aptose Biosciences Inc. - Quantisnow

Dec 13, 2024

Dec 12, 2024

Aptose Announces Publication of Preclinical Data in AACR - GlobeNewswire

Dec 12, 2024

Dec 12, 2024

Aptose's Tuspetinib Shows Breakthrough Potential in Leukemia Treatment, Clinical Data Reveals Powerful Anti-Cancer Effects - StockTitan

Dec 12, 2024

Dec 11, 2024

Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks On TSX (APS) - Barchart

Dec 11, 2024

Dec 09, 2024

Aptose Clinical Data Featured in Poster Presentation at the - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - Marketscreener.com

Dec 09, 2024

Dec 09, 2024

Aptose's Tuspetinib Shows Breakthrough 60% Response Rate in AML Treatment at ASH Meeting - StockTitan

Dec 09, 2024

Dec 07, 2024

StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World

Dec 07, 2024

Dec 04, 2024

Aptose Biosciences maintains shares target, Buy rating post-NCI deal By Investing.com - Investing.com Canada

Dec 04, 2024

Dec 03, 2024

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML - GlobeNewswire

Dec 03, 2024

Dec 03, 2024

Aptose Partners with NCI to Advance Tuspetinib Cancer Treatment in Clinical Trials - StockTitan

Dec 03, 2024

Nov 30, 2024

Aptose Biosciences Inc (APTO) Has A Gold Mine On Its Hands - Stocks Register

Nov 30, 2024

Nov 27, 2024

Aptose Biosciences CEO William Rice acquires $20,000 in shares By Investing.com - Investing.com Australia

Nov 27, 2024

Nov 26, 2024

Aptose Biosciences CEO William Rice acquires $20,000 in shares - Investing.com

Nov 26, 2024

Nov 26, 2024

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - GlobeNewswire

Nov 26, 2024

Nov 25, 2024

Aptose Biosciences Boosts Capital with $8M Offering - TipRanks

Nov 25, 2024

Nov 25, 2024

Aptose Biosciences Completes $8M Public Offering with Insider Participation | APTO Stock News - StockTitan

Nov 25, 2024

Nov 25, 2024

Form 424B4 Aptose Biosciences Inc. - StreetInsider.com

Nov 25, 2024

Nov 25, 2024

SEC Form 424B4 filed by Aptose Biosciences Inc. - Quantisnow

Nov 25, 2024

Nov 23, 2024

Aptose sets $8 million target in stock and warrant offering By Investing.com - Investing.com Australia

Nov 23, 2024

Nov 23, 2024

Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada

Nov 23, 2024

Nov 22, 2024

Crude Oil Gains Over 1%; Ross Stores Earnings Top Views - Benzinga

Nov 22, 2024

Nov 22, 2024

Aptose sets $8 million target in stock and warrant offering - Investing.com India

Nov 22, 2024

Nov 22, 2024

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering - GlobeNewswire

Nov 22, 2024

Nov 22, 2024

Dow Jumps 300 Points; Gap Posts Upbeat Earnings - Benzinga

Nov 22, 2024

Nov 22, 2024

Aptose Biosciences Inc. - Baystreet.ca

Nov 22, 2024

Nov 22, 2024

Aptose Biosciences Announces $8 Million Public Offering - TipRanks

Nov 22, 2024

Nov 22, 2024

Aptose Biosciences Raises $8M in Public Offering with Warrant Package at $0.20 Per Share | APTO Stock News - StockTitan

Nov 22, 2024

Nov 22, 2024

Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - Benzinga

Nov 22, 2024

Nov 21, 2024

Aptose Biosciences stock plunges to 52-week low of $0.33 By Investing.com - Investing.com Canada

Nov 21, 2024

Nov 20, 2024

Aptose Biosciences stock plunges to 52-week low of $0.33 - Investing.com India

Nov 20, 2024

Nov 20, 2024

Aptose Initiates TUSCANY Phase 1/2 Study for Newly - GlobeNewswire

Nov 20, 2024

Nov 20, 2024

Aptose Launches Phase 1/2 Trial Testing Novel AML Triplet Therapy with Tuspetinib | APTO Stock News - StockTitan

Nov 20, 2024

Nov 14, 2024

ARMISTICE CAPITAL, LLC Increases Stake in Aptose Biosciences Inc - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Aptose Biosciences Inc. (APTO) Quarterly 10-Q Report - Quartz

Nov 14, 2024

Nov 08, 2024

Aptose Biosciences Reports Q3 2024 Financial Highlights - TipRanks

Nov 08, 2024

Nov 08, 2024

Aptose Reports Results for the Third Quarter 2024 - GlobeNewswire

Nov 08, 2024

Nov 08, 2024

Aptose Biosciences Cuts Q3 Losses, Secures $10M Loan Amid Nasdaq Challenges | APTO Stock News - StockTitan

Nov 08, 2024

Oct 21, 2024

RNA-based Therapeutics Market Latest Trends Analysis Report 2024 - InsightAce Analytic

Oct 21, 2024

Oct 15, 2024

Hanmi and MEDiC ink cancer biomarker collaboration deal - Pharmaceutical Technology

Oct 15, 2024

Oct 05, 2024

Aptose Biosciences faces delisting from NASDAQ - Investing.com India

Oct 05, 2024

Oct 04, 2024

Aptose Biosciences faces delisting from NASDAQ By Investing.com - Investing.com South Africa

Oct 04, 2024

Sep 18, 2024

Analysts’ New Coverage for September 18th (AINC, AIRI, APTO, ARM, AVGO, BGNE, CAN, CARA, CHH, CLLS) - Defense World

Sep 18, 2024

Sep 09, 2024

Aptose Biosciences secures shareholder nod for warrant issuance - Investing.com

Sep 09, 2024

Sep 09, 2024

Aptose Biosciences stock hits 52-week low at $0.34 - Investing.com

Sep 09, 2024